Using DYRK1B-amplified pancreatic and ovarian cancer cells, co-targeting both kinases resulted in a significantly reduced GLI1 level and in increased cell death induction which could help to design new cancer therapies in the future. Here, DYRK1B is linked to ovarian carcinoma.